CMPS | COMPASS Pathways plc | [NASD]
Index- P/E- EPS (ttm)-2.22 Insider Own45.42% Shs Outstand42.73M Perf Week-5.09%
Market Cap341.27M Forward P/E- EPS next Y-2.53 Insider Trans0.00% Shs Float25.03M Perf Month-5.32%
Income-94.50M PEG- EPS next Q-0.68 Inst Own18.40% Short Float / Ratio10.89% / 10.16 Perf Quarter-9.14%
Sales- P/S- EPS this Y-20.20% Inst Trans2.60% Short Interest2.73M Perf Half Y-27.00%
Book/sh3.78 P/B2.02 EPS next Y1.20% ROA-45.40% Target Price42.30 Perf Year-1.54%
Cash/sh2.62 P/C2.91 EPS next 5Y- ROE-49.60% 52W Range6.97 - 21.50 Perf YTD-4.73%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-64.42% Beta-
Dividend %- Quick Ratio14.90 Sales past 5Y- Gross Margin- 52W Low9.76% ATR0.45
Employees114 Current Ratio14.90 Sales Q/Q- Oper. Margin- RSI (14)37.61 Volatility5.59% 5.20%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.50% Profit Margin- Rel Volume0.66 Prev Close7.48
ShortableYes LT Debt/Eq0.00 EarningsMay 11 BMO Payout- Avg Volume268.19K Price7.65
Recom1.60 SMA20-6.38% SMA50-15.47% SMA200-27.38% Volume178,040 Change2.27%
Date Action Analyst Rating Change Price Target Change
Nov-21-22Resumed Berenberg Buy $33
Nov-01-22Initiated Loop Capital Buy $34
Oct-29-21Initiated Oppenheimer Outperform $50
Jul-13-21Initiated Citigroup Buy $67
Jun-28-21Initiated Maxim Group Buy $70
May-11-21Initiated Cantor Fitzgerald Overweight $71
Apr-01-21Initiated ROTH Capital Buy $88
Oct-14-20Initiated H.C. Wainwright Buy $65
Oct-13-20Initiated Evercore ISI Outperform
Oct-13-20Initiated Cowen Outperform
Oct-13-20Initiated Berenberg Buy $50
May-26-23 04:00PM
May-11-23 12:30PM
May-06-23 09:37AM
04:01PM Loading…
May-03-23 04:01PM
May-02-23 07:00AM
Apr-20-23 08:55AM
Apr-10-23 10:10AM
Mar-12-23 12:22PM
Mar-06-23 08:50AM
Mar-02-23 10:23AM
12:12AM Loading…
Mar-01-23 12:12AM
Feb-28-23 02:00PM
Feb-24-23 12:01PM
Feb-12-23 02:21PM
Feb-07-23 05:52AM
Feb-06-23 08:28PM
Feb-05-23 02:30PM
Jan-27-23 09:40AM
Jan-13-23 12:00PM
Jan-11-23 09:40AM
Dec-08-22 04:00AM
Nov-29-22 10:00AM
Nov-28-22 04:01PM
Nov-04-22 12:16PM
01:00PM Loading…
Nov-03-22 01:00PM
Nov-02-22 05:10PM
Oct-29-22 09:50AM
Oct-26-22 04:00PM
Oct-25-22 12:00PM
Oct-12-22 11:00AM
Oct-04-22 09:05AM
Sep-28-22 10:30AM
Sep-27-22 08:36AM
Sep-19-22 04:01PM
Sep-12-22 05:30AM
Sep-09-22 10:37AM
Sep-05-22 10:45AM
Sep-01-22 08:06AM
Aug-30-22 03:02PM
Aug-25-22 04:41PM
Aug-21-22 10:27AM
Aug-20-22 08:03AM
Aug-16-22 03:40PM
Aug-09-22 09:43PM
Aug-08-22 09:55AM
Aug-04-22 07:30PM
Aug-02-22 04:05PM
Aug-01-22 08:00AM
Jul-28-22 04:00AM
Jul-26-22 08:00AM
Jul-19-22 08:00AM
Jun-03-22 09:55AM
May-23-22 07:00AM
May-22-22 09:26AM
May-12-22 08:00AM
May-10-22 12:30PM
May-09-22 07:00AM
May-03-22 08:00AM
Apr-20-22 07:00AM
Apr-19-22 08:07AM
Apr-12-22 12:44PM
Apr-04-22 08:00AM
Mar-24-22 05:00AM
Mar-02-22 07:00AM
Feb-24-22 07:30PM
Feb-17-22 12:21PM
Jan-19-22 07:00AM
Jan-10-22 07:00AM
Jan-04-22 07:00AM
Dec-23-21 06:48AM
Dec-22-21 01:43PM
Dec-17-21 07:00AM
Dec-16-21 07:40AM
Dec-13-21 07:00AM
Dec-08-21 06:48PM
Dec-06-21 07:01AM
Dec-03-21 07:00AM
Dec-01-21 07:00AM
Nov-30-21 08:00AM
Nov-29-21 07:00AM
Nov-28-21 07:17AM
Nov-23-21 07:00AM
Nov-21-21 06:45AM
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.